Ketamine and damage to the urinary tract

Wood, Dan

doi:10.1111/add.12228

Cited by 29 publications

(8 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the limited studies involving repeated dosing of mood disorder patients, report the treatment has been generally well-tolerated, and there have been no reports raising the level of concern related to cognitive difficulties for mood disordered patients (aan het Rot et al, 2010;Blier et al, 2012;Shiroma et al, 2014). The known risk of urinary cystitis associated repeated ketamine administration appears to be associated with very high levels of use for prolonged periods (Tam et al, 2014;Wood, 2013), but it remains another concern that needs to be considered with longer-term treatment strategies. Moreover, ketamine is known to be a drug of abuse, raising the additional concerns that repeated administration of the drug could have a liability for drug abuse.…”

Section: Schatzberg)mentioning

confidence: 99%

Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders?

Sanacora

Schatzberg

2014

Neuropsychopharmacol

141

124

View full text Add to dashboard Cite

Large 'real world' studies demonstrating the limited effectiveness and slow onset of clinical response associated with our existing antidepressant medications has highlighted the need for the development of new therapeutic strategies for major depression and other mood disorders. Yet, despite intense research efforts, the field has had little success in developing antidepressant treatments with fundamentally novel mechanisms of action over the past six decades, leaving the field wary and skeptical about any new developments. However, a series of relatively small proof-of-concept studies conducted over the last 15 years has gradually gained great interest by providing strong evidence that a unique, rapid onset of sustained, but still temporally limited, antidepressant effects can be achieved with a single administration of ketamine. We are now left with several questions regarding the true clinical meaningfulness of the findings and the mechanisms underlying the antidepressant action. In this Circumspectives piece, Dr Sanacora and Dr Schatzberg share their opinions on these issues and discuss paths to move the field forward.

show abstract

Section: Schatzberg)mentioning

confidence: 99%

Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders?

Sanacora

Schatzberg

2014

Neuropsychopharmacol

141

124

View full text Add to dashboard Cite

show abstract

“…These risks include neurocognitive dysfunction, the development of urinary cystitis, and adverse changes in brain structure and function. [69][70][71][72] Very few studies have assessed the risks of these potential concerns with ketamine in depressed patients. In a secondary analysis of data from a randomized short-term antidepressive efficacy trial, [73] neurocognitive performance was measured using components of the MATRICS Consensus Cognitive Battery [74] before study drug infusion, and at 24, 48, and 72 hrs, and 7 days postadministration.…”

Section: Longer-term Safety and Effectivenessmentioning

confidence: 99%

Ketamine for Treatment-Resistant Unipolar and Bipolar Major Depression: Critical Review and Implications for Clinical Practice

et al. 2016

View full text Add to dashboard Cite

There is an urgent need for more rapidly effective pharmacotherapies for major depressive disorder and bipolar disorder (BP) that are efficacious and tolerable for depressed patients who respond poorly to conventional treatments. Multiple controlled trials have now demonstrated a rapid, nonsustained antidepressive response to a single intravenous infusion of ketamine. Early controlled studies of intranasal or serial infusion therapy appear promising. The effective dose for depression is lower than the typical anesthetic doses, and side-effects are generally mild and transient. The data investigating the adjunctive use of concurrent ketamine in the course of electroconvulsive therapy (ECT) for depression do not suggest efficacy or tolerability. The therapeutic potential of ketamine has stimulated considerable excitement among clinicians, patients, and industry, and has led to the increasing use of ketamine as an off-label substitute for ECT and other antidepressive treatments. This clinical review of ketamine will assess the evidence-based use of ketamine and initial clinical implications of further development of a potentially novel treatment for rapid reduction of symptoms in depressed patients.

show abstract

“…More than 10,000 published reports describe ketamine's high level of effectiveness and its confirmed biological safety in most cases, although like all drugs there is the possibility of some adverse effects in some people (Bauman, Kish, Baumann, & Politis, 1999;Dachs & Innes, 1997;Ersek, 2004;Reich & Silvay, 1989;Ross & Fochtman, 1995;Shapiro, Wyte, & Harris, 1972). Clinical studies have generally detected no long-term impairment of behavior or personality functioning as a result of repeated ketamine use (Siegal, 1978), but some individual case studies of ketamine dependence have raised questions at times (e.g., Jansen 1990, summary in Jansen 2001 and there have been some recent concerns about, for example, toxicity to the urinary system (e.g., Selby et al, 2008;Wood, 2013. ) According to several in vitro and animal studies, ketamine can even have neuroprotective properties under some circumstances Shapira, Artru, & Lam, 1992;Shapira, Lam, Eng, Laohaprasit, & Michel, 1994).…”

mentioning

confidence: 99%

Ketamine Psychedelic Psychotherapy: Focus on its Pharmacology, Phenomenology, and Clinical Applications

Kolp¹,

Friedman²,

Krupitsky³

et al. 2014

IJTS

View full text Add to dashboard Cite

Meant to be an authoritative guide for psychiatrists and others interested in understanding and applying ketamine psychedelic psychotherapy (KPP), this paper focuses on its pharmacology, phenomenology, and clinical applications. Ketamine is a dissociative anesthetic widely used by physicians and veterinarians in the United States. In addition to its anesthetic and dissociative properties, ketamine also has a multitude of other psychological and pharmacological properties, which include analgesic, sedative, neuroprotective, anxiolytic, antidepressant, stimulant, euphoriant, and hallucinogenic effects. The literature on the clinical application of KPP is comprehensively reviewed, practical advice for using KPP is given, and the pharmacology and phenomenology of ketamine-induced psychedelic experiences are explored, including in relationship to transpersonal healing and possible iatrogenic consequences of misuse of KPP.

show abstract

Ketamine and damage to the urinary tract

Cited by 29 publications

References 5 publications

Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders?

Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders?

Ketamine for Treatment-Resistant Unipolar and Bipolar Major Depression: Critical Review and Implications for Clinical Practice

Ketamine Psychedelic Psychotherapy: Focus on its Pharmacology, Phenomenology, and Clinical Applications

Contact Info

Product

Resources

About